Lexaria Bioscience Corp. announced on December 17, 2024, the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson is an esteemed Harvard Medical School Professor.
In his new role, Dr. Gibson will collaborate directly with President and Chief Scientific Officer John Docherty. His expertise will guide the expansion of Lexaria's patented DehydraTECH drug delivery platform.
Dr. Gibson's appointment is expected to bolster Lexaria's strategic development plans, particularly as the company continues to expand its applications in the GLP-1 and hypertension therapeutic areas. He will also join Lexaria's new scientific advisory board.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.